- Home
- RYDE vs GTBP Comparison
RYDE vs GTBP Comparison
Compare RYDE & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- GTBP
- Stock Information
- Founded
- RYDE 2014
- GTBP 1965
- Country
- RYDE Singapore
- GTBP United States
- Employees
- RYDE N/A
- GTBP N/A
- Industry
- RYDE
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- GTBP Health Care
- Exchange
- RYDE NYSE
- GTBP Nasdaq
- Market Cap
- RYDE 5.2M
- GTBP 5.5M
- IPO Year
- RYDE 2024
- GTBP N/A
- Fundamental
- Price
- RYDE $0.36
- GTBP $2.13
- Analyst Decision
- RYDE
- GTBP Strong Buy
- Analyst Count
- RYDE 0
- GTBP 1
- Target Price
- RYDE N/A
- GTBP $11.00
- AVG Volume (30 Days)
- RYDE 29.7M
- GTBP 119.8K
- Earning Date
- RYDE 05-02-2025
- GTBP 08-13-2025
- Dividend Yield
- RYDE N/A
- GTBP N/A
- EPS Growth
- RYDE N/A
- GTBP N/A
- EPS
- RYDE N/A
- GTBP N/A
- Revenue
- RYDE $6,557,978.00
- GTBP N/A
- Revenue This Year
- RYDE $21.13
- GTBP N/A
- Revenue Next Year
- RYDE $13.43
- GTBP N/A
- P/E Ratio
- RYDE N/A
- GTBP N/A
- Revenue Growth
- RYDE 3.27
- GTBP N/A
- 52 Week Low
- RYDE $0.16
- GTBP $1.72
- 52 Week High
- RYDE $22.49
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- GTBP 34.57
- Support Level
- RYDE N/A
- GTBP $1.91
- Resistance Level
- RYDE N/A
- GTBP $3.73
- Average True Range (ATR)
- RYDE 0.00
- GTBP 0.33
- MACD
- RYDE 0.00
- GTBP -0.17
- Stochastic Oscillator
- RYDE 0.00
- GTBP 11.34
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.